

Therapeutic targeting of autophagy in myocardial infarction and heart failure

Por: [Riquelme, JA](#) (Riquelme, Jaime A.)^[1,2,3]; [Chavez, MN](#) (Chavez, Myra N.)^[1,2,3,4]; [Mondaca-Ruff, D](#) (Mondaca-Ruff, David)^[1,2,3]; [Bustamante, M](#) (Bustamante, Mario)^[1,2,3,5]; [Vicencio, JM](#) (Miguel Vicencio, Jose)^[1,2,3,6]; [Quest, AFG](#) (Quest, Andrew F. G.)^[1,2,3]; [Lavandero, S](#) (Lavandero, Sergio)^[1,2,3,7]

EXPERT REVIEW OF CARDIOVASCULAR THERAPY

Volumen: 14

Número: 9

Páginas: 1007-1019

DOI: 10.1080/14779072.2016.1202760

Fecha de publicación: 2016

Resumen

Introduction: Myocardial infarction (MI) is the leading cause of death. When MI is not lethal, heart failure (HF) is a major consequence with high prevalence and poor prognosis. The targeting of autophagy represents a potentially therapeutic approach for the treatment of both pathologies.

Areas covered: PubMed searches were performed to discuss the current state of the art regarding the role of autophagy in MI and HF. We review available and potential approaches to modulate autophagy from a pharmacological and genetic perspective. We also discuss the targeting of autophagy in myocardial regeneration.

Expert commentary: The targeting of autophagy has potential for the treatment of MI and HF. Autophagy is a process that takes place in virtually all cells of the body and thus, in order to evaluate this therapeutic approach in clinical trials, strategies that specifically target this process in the myocardium is required to avoid unwanted effects in other organs.

Palabras clave

Palabras clave de autor: [Autophagy](#); [cell death](#); [ischemia reperfusion](#); [myocardial infarction](#); [heart failure](#); [pharmacological target](#)

KeyWords Plus: [ISCHEMIA-REPERFUSION INJURY](#); [MESENCHYMAL STEM-CELLS](#); [IMPROVES CARDIAC-FUNCTION](#); [ACTIVATED PROTEIN-KINASE](#); [REGULATES AUTOPHAGY](#); [NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE](#); [ISCHEMIA/REPERFUSION INJURY](#); [CARDIOMYOCYTE AUTOPHAGY](#); [INHIBITS AUTOPHAGY](#); [EUROPEAN-SOCIETY](#)

Información del autor

Dirección para petición de copias: Lavandero, S (autor para petición de copias)



Univ Chile, Fac Ciencias Quim & Farmaceut, Adv Ctr Chron Dis ACCDiS, Olivos 1007, Santiago 8380492, Chile.

Direcciones:

- + [1] Univ Chile, Fac Ciencias Quim & Farmaceut, Adv Ctr Chron Dis ACCDiS, Olivos 1007, Santiago 8380492, C
- + [2] Univ Chile, Fac Ciencias Quim & Farmaceut, Ctr Mol Studies Cell CEMC, Santiago, Chile
- + [3] Univ Chile, Fac Med, Santiago, Chile
- + [4] Univ Chile, Fac Ciencias, FONDAF Ctr Genome Regulat, Santiago, Chile
- + [5] Pontificia Univ Catolica Chile, Fac Med, Div Enfermedades Cardiovasc, Adv Ctr Chron Dis ACCDiS, Santiag
- + [6] UCL, Canc Inst, London, England
- + [7] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dept Internal Med, Dallas, TX 75390 USA

Direcciones de correo electrónico: slavander@uchile.cl

Editorial

TAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA

Categorías / Clasificación

Áreas de investigación: Cardiovascular System & Cardiology

Categorías de Web of Science: Cardiac & Cardiovascular Systems

Información del documento

Tipo de documento: Review

Idioma: English

Número de acceso: **WOS:000390925300005**

ID de PubMed: 27308848

ISSN: 1477-9072

eISSN: 1744-8344

Otra información

Número IDS: EG3DZ

Referencias citadas en la Colección principal de Web of Science: **138**

Veces citado en la Colección principal de Web of Science: **4**